Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Wikidata - awgldk - TriplyDB

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

http://www.wikidata.org/entity/Q38994327

about

MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition Lung adenocarcinoma: from molecular basis to genome-guided therapy and immunotherapy.Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer.A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.MET inhibitors in advanced non-small-cell lung cancer: a meta-analysis and review.Current Landscape of Targeted Therapy in Lung Cancer.Emerging uses of biomarkers in lung cancer management: molecular mechanisms of resistance.The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.Understanding and targeting resistance mechanisms in NSCLC.About MET expression and other biomarkers in non-small cell lung cancer.Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer.[Progress of c-MET Signaling Pathway and TKIs in Non-small Cell Lung Cancer].Targeting MET in cancer therapy.Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.MET amplification assessed using optimized FISH reporting criteria predicts early distant metastasis in patients with non-small cell lung cancer.An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer.Identification of candidate genes or microRNAs associated with the lymph node metastasis of SCLC

P2860

Q36265149-AD85DD8B-A2C8-4F34-91FA-B177BCCBB219 Q40070868-1A6BB68F-5DEF-4536-A2DA-F9E4235BE407 Q42369856-4A4F63F0-B4A6-4395-8B40-9FEE469F759A Q42378367-7258968D-8A18-474B-BE0F-2B7DA11D0EF9 Q45968290-2DD32FBC-490D-442A-90C2-D95B28669CBE Q46034707-E6DF6FDD-0DB7-4746-857E-A387FAB015CA Q46071509-3B5DE4A7-7A03-40B7-B037-FC9293F3FB76 Q46073425-B483BA9E-6A5F-4471-AE45-727691B21609 Q46915997-D8983AFD-BBA2-4FCA-BB18-1E8E9A5C1F51 Q48142691-C83A2A66-7BBC-4F3C-9D9E-E56C52063A11 Q52312436-688DEF26-246F-46F8-B1DE-EBEE918B801E Q53742581-BBA81BD9-A4A4-40D4-965C-08D2E57A1235 Q54987450-E6291A4C-B8F9-4B01-A134-52E60D9DB2EC Q55191884-9FF4DB2A-01D2-4D69-9CE2-A1B5832F5536 Q55347158-53056E5E-AE6C-45B9-B9B2-A37C6DE1E3A2 Q55515425-6FBED685-1A70-4E29-95A0-B372A0E37741 Q58586691-E27450FC-F13D-46EF-842F-8AB777EEE2CE

P2860

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

http://www.wikidata.org/entity/Q38994327

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

@en

type

label

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

@en

prefLabel

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

@en

P1433

Q38994327-59A13973-4AB9-4054-8606-2B52F6E49A3D

P1476

Q38994327-725BBE2E-1B33-48AF-86F3-C39EE21F8A3D

P2093

Q38994327-666EF092-BA92-4567-AD87-89B282C1A10A

Q38994327-7AA999D3-8EFA-40A6-B977-E53D371F0AD3

Q38994327-B6361A78-FDBB-4E8B-A90A-37882C095C86

P2860

Q38994327-01036A61-7177-4442-B04E-126F6EF918D2

Q38994327-02969E7A-CFAF-466E-B65F-3E0F86AE0B79

Q38994327-0D04364C-DEB9-4B5E-8A21-F25228F8E590

Q38994327-0D6D03E1-5DB4-4F9D-9108-A681A87607FF

Q38994327-0E12B3E5-4487-4A6D-80B3-7F02C5A359DE

Q38994327-1005B7FF-FE8E-4651-AB98-FE858B67B301

Q38994327-14777770-21FF-4DFD-BF5C-214D981C46FC

Q38994327-1650EE33-3F29-4077-8AA3-E2D2AED0B765

Q38994327-1684DBF8-31D6-40E3-96BD-7298AEAC8997

Q38994327-29C23281-D2EF-4DFC-AD84-B28E1CD4E5C8

P304

Q38994327-1A87DF59-12B1-40B5-B3B7-90B9C5D2A285

P31

Q38994327-F77B4B22-0069-4639-92D3-A7C1060FE7FE

P356

Q38994327-89B60267-A126-4C80-A75F-7B53408F721C

P433

Q38994327-505B58F5-6BBB-430A-AEA2-8E20F8788626

P478

Q38994327-FA8E3C64-37D3-4D3B-A039-FBFFE01CB169

P50

Q38994327-B330732C-B791-4A3E-9173-0A87116148D7

P577

Q38994327-357891E0-C40D-4040-9C90-34470AEA1CF1

P698

Q38994327-F26362E8-7618-4B6D-95BC-EC0433C1E0C8

P932

Q38994327-45ADC42D-B885-4CED-A7BA-79D6F24CE091

P356

J.JTHO.2016.10.014

P1433

Journal of Thoracic Oncology

P1476

Targeting MET in Lung Cancer: Will Expectations Finally Be MET?

@en

P2093

Alexander Drilon

http://www.w3.org/2001/XMLSchema#string

D Ross Camidge

http://www.w3.org/2001/XMLSchema#string

Federico Cappuzzo

http://www.w3.org/2001/XMLSchema#string

P2860

An overview of the c-MET signaling pathway

MET gene copy number predicts worse overall survival in patients with non-small cell lung cancer (NSCLC); a systematic review and meta-analysis

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification.

Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M.

Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors.

Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping

P304

15-26

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JTHO.2016.10.014

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Sai-Hong Ignatius Ou

P577

2016-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27794501

http://www.w3.org/2001/XMLSchema#string

P932

5603268

http://www.w3.org/2001/XMLSchema#string